GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chongqing Lummy Pharmaceutical (SZSE:300006) » Definitions » 3-Year EBITDA Growth Rate

Chongqing Lummy Pharmaceutical (SZSE:300006) 3-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Chongqing Lummy Pharmaceutical 3-Year EBITDA Growth Rate?

Chongqing Lummy Pharmaceutical's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Chongqing Lummy Pharmaceutical was 33.30% per year. The lowest was -85.60% per year. And the median was 5.15% per year.


Competitive Comparison of Chongqing Lummy Pharmaceutical's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Chongqing Lummy Pharmaceutical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Lummy Pharmaceutical's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chongqing Lummy Pharmaceutical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Chongqing Lummy Pharmaceutical's 3-Year EBITDA Growth Rate falls into.



Chongqing Lummy Pharmaceutical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Chongqing Lummy Pharmaceutical  (SZSE:300006) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Chongqing Lummy Pharmaceutical 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Chongqing Lummy Pharmaceutical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Lummy Pharmaceutical (SZSE:300006) Business Description

Traded in Other Exchanges
N/A
Address
99 Yuma Road, Nan'an District, chongqing, CHN, 401123
Chongqing Lummy Pharmaceutical is a wholly-owned subsidiary of Lai America Pharmaceutical Co., Ltd. and is a professional pharmaceutical sales company in China.
Executives
Yuan Yuan Supervisors
Qiu Yu Directors, executives
Leng Xue Feng Secretary, Director
Zhang Xiao Xue Supervisors
Wang Ying Director
Zhou Xue Mei Supervisors
Zhao Bin Executives
Tang Xiao Hai Executives
Fu Rong Executives
Li Xian Feng Supervisors
Qiu Wei Director

Chongqing Lummy Pharmaceutical (SZSE:300006) Headlines

No Headlines